UGP logo

UGP Cost of Revenue

Latest reportedR$141.23B BRL
UGP TTM Cost of Revenue · BRL (R$1.42B → R$141.23B)
High-resolution chart · PNG

UGP cost of revenue history

Trailing twelve months (TTM) · BRL. Each value covers four complete reported quarters.

Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) Cost of Revenue — Trailing twelve months (TTM) (BRL)
Period endingCost of Revenue (BRL)
141,233,369,087
135,400,700,000
133,010,699,000
130,888,362,000
129,407,584,000
127,736,103,000
124,883,162,000
121,997,954,000
118,541,711,000
116,226,125,000
116,730,469,000
120,856,038,000
128,945,435,000
136,052,679,000
137,247,257,000
133,143,977,000
123,705,523,000
114,072,374,000
104,827,967,000
96,156,468,000
87,009,589,000
76,440,228,000
75,628,214,000
75,950,869,000
78,407,737,000
83,869,627,000
83,187,109,000
83,073,634,000
83,702,573,000
84,602,216,000
84,537,368,000
82,274,946,000
78,520,732,000
74,924,755,000
72,735,781,000
70,355,797,000
69,563,166,000
69,577,494,000
70,342,723,000
71,707,053,000
71,555,117,000
70,918,235,000
68,933,702,000
66,632,392,000
65,051,926,000
63,451,307,000
62,304,631,000
60,911,916,000
59,627,518,000
58,303,871,000
56,165,382,000
54,450,896,000
52,842,405,000
50,836,632,000
49,797,200,000
48,413,136,000
47,358,878,000
46,656,187,000
45,139,601,000
43,703,275,000
41,826,343,000
40,045,549,000
39,281,572,000
38,543,110,000
37,370,180,000
36,743,184,000
33,412,000,000
30,478,455,696
28,843,655,244
26,415,936,048
25,982,351,368
25,171,995,274
23,540,079,674
22,744,428,017
18,242,085,234
13,261,528,786
8,632,147,000
3,894,296,217
3,851,185,853
3,843,966,333
3,819,514,186
3,797,156,638
3,770,011,454
3,763,226,215
3,750,412,833
3,709,304,660
3,661,790,934
3,606,374,121
3,443,233,734
3,273,719,757
3,189,028,956
3,077,210,470
2,817,741,162
2,579,547,656
2,262,193,570
1,970,822,466
1,828,806,059
1,739,112,421
1,704,764,564
1,680,688,048
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.